Its ability to reduce food intake by enhancing satiety further supports individuals in their weight management efforts, a common challenge among those with type 2 diabetes
Results The model detected 112,274 T2D patients who did not receive insulin therapy and started GLP1-receptor agonists (28,081 individuals) or SGLT2 inhibitors (84,193 individuals) in the United Kingdom (UK) from January 2013 to October 2020
Wong HJ, Sim B, Teo YH, et al
Reducing appetite signals sent to the brain
Director Steven Dudley said it has become popular because of the drug's dramatic weight-loss effects
If you want a clear-eyed look at the numbers, our GH Secretagogue Profit Margin and ROI Guide for Clinics walks through realistic cost structures, patient pricing models, and what to watch out for